Targeting IL-30 in the TME, besides directly affecting cancer cell viability, subverts the cancer progression program and weakens the complicity between cancer and myeloid cells, providing a valuable tool to improve the response to a T cell-based immunotherapy that is customizable on patients with IL-30-expressing malignancies. Here, IL27 is linked to cancer.